Trial Profile
A Retrospective study of Nivolumab and Antibiotic use in Patients with Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Lung cancer; Small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 21 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology